Komori
Jgc Holdings (1963) · InitiativeRestated

Continued Research and Development Activity

First written in FY2018-Q1. 21 of 27 entries say "Restated". Latest entry: FY2027-H1.

27entries
10years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2019-Q1 – FY2020-Q3RestatedFY2021-Q1 – FY2022-Q3RestatedFY2024-Q1 – 2026-05-142017: 220172018: 420182019: 320192020: 420202021: 220212022: 420222023: 320232024: 120242025: 020252026: 42026
Same theme, other companies
Continuation of R&D activities with no change in statusA theme 222 companies write about · 0 as a headwind · 211 as a tailwind

94 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 196 companies compared. The sentences above are computed from all 196.Comparing 200 of the theme's 226 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2027-H1RestatedAnnual report

    「The Group's total R&D expenses for the current interim consolidated accounting period were ¥4,669 million. There were no material changes in the status of the Group's R&D activities during the current interim consolidated accounting period.」

    There were reportedly no material changes in R&D activities, and R&D expenses for the current interim consolidated accounting period were ¥4,669 million.
  2. FY2026AdvancedAnnual report

    「As part of these efforts, the Company completed construction of a bioprocess research institute on Port Island in Kobe to develop the world's first gas-circulation fermentation process using CO2 as a feedstock. In addition, in the sustainable aviation fuel (SAF) sector, the Company completed construction of Japan's first large-scale SAF production facility and began supplying SAF to airlines. Total R&D expenses for the current consolidated fiscal year were ¥8,745 million.」

    R&D activities produced specific results, including completion of the bioprocess research institute and the large-scale SAF production facility, as well as the start of SAF supply. Annual R&D expenses were ¥8,745 million.
  3. FY2024-Q3RestatedAnnual report

    「The Group's R&D expenses for the nine months ended 31 December were ¥8,341 million . There were no material changes in the status of the Group's R&D activities during the nine months ended 31 December.」

    There were reportedly no material changes in R&D activities, and R&D expenses for the third quarter of the current consolidated cumulative period were ¥8,341 million.
  4. FY2024-Q1RestatedAnnual report

    「The Group's total R&D expenses for the first quarter of the current consolidated cumulative period were ¥2,413 million. There were no material changes in the status of the Group's R&D activities during the first quarter of the current consolidated cumulative period.」

    There were no material changes in R&D activities, and R&D expenses for the first quarter of the current consolidated cumulative period were ¥2,413 million.
  5. FY2023AdvancedAnnual report

    「As a result, in addition to continuing to promote demonstration projects aimed at the early acquisition of technologies that will become the core of future businesses, the Group was able to promote new demonstration projects, establish special-purpose companies to advance its businesses, build partnerships with relevant parties to promote commercialization, and foster new industry-academia collaboration. R&D expenses include ¥2,096 million in R&D costs incurred by the Company that cannot be allocated to individual segments, and total R&D expenses for the current consolidated fiscal year were ¥7,862 million.」

    R&D activities progressed through existing and new demonstration projects, the establishment of special-purpose companies to advance businesses, and collaboration with relevant parties and academia and industry. Annual R&D expenses were ¥7,862 million.
  6. FY2023-Q3RestatedAnnual report

    「The Group's total R&D expenses for the third quarter of the current consolidated cumulative period were ¥6,077 million. There were no material changes in the status of the Group's R&D activities during the third quarter of the current consolidated cumulative period.」

    There were reportedly no material changes in R&D activities, and R&D expenses for the third quarter of the current consolidated cumulative period were ¥6,077 million.
  7. FY2023-Q2RestatedAnnual report

    「The Group's total R&D expenses for the second quarter of the current consolidated cumulative period were ¥4,183 million. There were no material changes in the status of the Group's R&D activities during the second quarter of the current consolidated cumulative period.」

    There were reportedly no material changes in R&D activities, and R&D expenses for the second quarter of the current consolidated cumulative period were ¥4,183 million.
  8. FY2023-Q1RestatedAnnual report

    「The Group's total R&D expenses for the first quarter of the current consolidated cumulative period were ¥1,980 million. There were no material changes in the status of the Group's R&D activities during the first quarter of the current consolidated cumulative period.」

    There were reportedly no material changes in R&D activities, and R&D expenses for the quarter were ¥1,980 million.
  9. FY2022AdvancedAnnual report

    「As a result, the Company was able to promote demonstration projects aimed at acquiring at an early stage technologies that will form the core of future businesses, acquire licensed technologies, build collaboration with relevant parties to promote commercialization, and advance new industry-academia collaboration. Total research and development expenses for the current consolidated fiscal year were ¥6,987 million.」

    The research and development section records progress in demonstrations, the acquisition of licensed technologies, commercialization partnerships and industry-academia collaboration, as well as annual research and development expenses of ¥6,987 million.
  10. FY2022-Q3RestatedAnnual report

    「Research and development expenses for the group as a whole during the nine-month period ended the third quarter were ¥5.401 billion. There were no material changes in the status of the group's research and development activities during the period.」

    There were no significant changes in research and development activities, and research and development expenses for the cumulative third quarter amounted to ¥5,401 million.
  11. FY2022-Q1RestatedAnnual report

    「Group-wide research and development expenses for the cumulative first quarter of the current consolidated fiscal year were ¥1,817 million. There were no significant changes in the status of the Group’s research and development activities during the cumulative first quarter of the current consolidated fiscal year.」

    There were no significant changes in research and development activities, and first-quarter research and development expenses amounted to ¥1,817 million.
  12. FY2021-Q3RestatedAnnual report

    「Group-wide research and development expenses for the cumulative third quarter of the current consolidated fiscal year were ¥5,362 million (excluding consumption taxes and other taxes). There were no significant changes in the status of the Group’s research and development activities during the cumulative third quarter of the current consolidated fiscal year.」

    There were no significant changes in research and development activities, and research and development expenses for the cumulative third quarter of the current fiscal year amounted to ¥5,362 million.
  13. FY2021-Q2RestatedAnnual report

    「Group-wide research and development expenses for the cumulative second quarter of the current consolidated fiscal year were ¥3,522 million (excluding consumption taxes and other taxes). There were no significant changes in the status of the Group’s research and development activities during the cumulative second quarter of the current consolidated fiscal year.」

    There were no significant changes in research and development activities, and first-half research and development expenses of ¥3,522 million were recorded.
  14. FY2021-Q1RestatedAnnual report

    「Group-wide research and development expenses for the cumulative first quarter of the current consolidated fiscal year were ¥1,829 million (excluding consumption taxes and other taxes). There were no significant changes in the status of the Group’s research and development activities during the cumulative first quarter of the current consolidated fiscal year.」

    There were no significant changes in research and development activities, and first-quarter research and development expenses amounted to ¥1,829 million.
  15. FY2020AdvancedAnnual report

    「As a result, the Company achieved results including project orders and technology licensing, and was able to accelerate industry-government-academia collaborative development aimed at acquiring at an early stage technologies that will form the core of future businesses in growth fields. Total research and development expenses for the current consolidated fiscal year were ¥6,861 million.」

    The research and development section records achievements in project orders and technology licensing, as well as annual research and development expenses of ¥6,861 million.
  16. FY2020-Q3RestatedAnnual report

    「Research and development expenses for the group as a whole during the nine-month period ended the third quarter were ¥4.935 billion, excluding consumption taxes and other taxes. There were no material changes in the status of the group's research and development activities during the period.」

    There were no significant changes in research and development activities, and research and development expenses for the cumulative third quarter of the current fiscal year were reported at ¥4,935 million.
  17. FY2020-Q2RestatedAnnual report

    「Group-wide research and development expenses for the cumulative second quarter of the current consolidated fiscal year were ¥3,324 million (excluding consumption taxes and other taxes). There were no significant changes in the status of the Group’s research and development activities during the cumulative second quarter of the current consolidated fiscal year.」

    There were no significant changes in research and development activities, and research and development expenses for the cumulative second quarter of the current fiscal year were reported at ¥3,324 million.
  18. FY2020-Q1RestatedAnnual report

    「Group-wide research and development expenses for the cumulative first quarter of the current consolidated fiscal year were ¥1,704 million (excluding consumption taxes and other taxes). There were no significant changes in the status of the Group’s research and development activities during the cumulative first quarter of the current consolidated fiscal year.」

    There were no significant changes in research and development activities, and research and development expenses for the cumulative first quarter of the current fiscal year were reported at ¥1,704 million.
  19. FY2019-Q3RestatedAnnual report

    「Research and development expenses for the group as a whole during the nine-month period ended the third quarter were ¥4.058 billion, excluding consumption taxes and other taxes. There were no material changes in the status of the group's research and development activities during the period.」

    The Company stated that there were no significant changes in research and development activities, and research and development expenses for the cumulative third quarter of the current consolidated fiscal year were reported at ¥4,058 million.
  20. FY2019-Q2RestatedAnnual report

    「Research and development expenses for the group as a whole during the six-month period ended the second quarter were ¥2.607 billion, excluding consumption taxes and other taxes. There were no material changes in the status of the group's research and development activities during the period.」

    The Company stated that there were no significant changes in research and development activities and recorded research and development expenses of ¥2,607 million for the current cumulative quarter.
  21. FY2019-Q1RestatedAnnual report

    「Research and development expenses for the group as a whole during the three-month period ended the first quarter were ¥1.301 billion, excluding consumption taxes and other taxes. There were no material changes in the status of the group's research and development activities during the period.」

    The Company stated that there were no significant changes in research and development activities and recorded research and development expenses of ¥1,301 million for the current cumulative quarter.
  22. FY2018AdvancedAnnual report

    「In the current consolidated fiscal year, the second year of the medium-term management plan “Beyond the Horizon,” the Company promoted business development based on differentiated technologies. Its priority strategies were (1) the early commercialization of technologies under development and expansion of the licensing business, (2) the creation and promotion of new businesses in growth fields, and (3) stronger collaboration with external parties through open innovation. The Company focused on resources, the environment, life sciences, new energy and manufacturing. As a result, it achieved results including the licensing of technologies overseas and was able to accelerate industry-government-academia collaborative development aimed at acquiring at an early stage technologies that will form the core of future businesses in growth fields. Total research and development expenses for the current consolidated fiscal year were ¥5,875 million (excluding consumption taxes and other taxes).」

    The priority strategies for research and development were organized into 3 areas, with achievements including overseas technology licensing and annual research and development expenses of ¥5,875 million recorded.
  23. FY2018-Q3RestatedAnnual report

    「Research and development expenses for the group as a whole during the nine-month period ended the third quarter were ¥4.461 billion, excluding consumption taxes and other taxes. There were no material changes in the status of the group's research and development activities during the period.」

    There were no significant changes in research and development activities, and research and development expenses for the cumulative third quarter of the current consolidated fiscal year were reported at ¥4,461 million.
  24. FY2018-Q2RestatedAnnual report

    「Research and development expenses for the group as a whole during the six-month period ended the second quarter were ¥3.06 billion, excluding consumption taxes and other taxes. There were no material changes in the status of the group's research and development activities during the period.」

    There were no significant changes in research and development activities, and research and development expenses for the current cumulative quarter were reported at ¥3,060 million.
  25. FY2018-Q1First statedAnnual report

    「Group-wide research and development expenses for the cumulative first quarter of the current consolidated fiscal year were ¥1,435 million (excluding consumption taxes and other taxes).」

    Research and development expenses of ¥1,435 million were reported for the current cumulative quarter, and research and development activities continued.
Moved together

"Negative Cash Flow from Operating Activities" moved the same way as this thread, in the same document, in 5 of its 27 moves.

544444★123456
  1. ★This thread
  2. 1Negative Cash Flow from Operating Activities5×
  3. 2Expansion of the domestic market share, applications and sales of the catalyst business4×
  4. 3Outstanding guarantee obligations4×
  5. 4Improving EPC business efficiency and transforming project management through AI and IoT4×
  6. 5Demonstration of a CO2-free ammonia production system4×
  7. 6Full-scale entry into the offshore wind power generation sector4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Jgc Holdings's next results are scheduled for 2026-11-11. Read the earnings preview It last moved in the Management Plan of 2026-05-14: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.